ImageneBio, Inc.: 5%+ holders

As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of ImageneBio, Inc. The largest reported stake is Orbimed Advisors LLC's, at 13.1%. 16 filings are on record since July 28, 2025 (Schedule 13D/A, April 29, 2026).

Jean-Francois Formela is also named on 1 other Form D filing ↓

Sell to companies like ImageneBio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-14 · Reporting person: Biotechnology Value Fund L P · Sole voting: 0 · Shared voting: 611,834 · Sole dispositive: 0 · Shared dispositive: 611,834 · SCHEDULE 13G/A, 2026-08-14
• Filed 2026-05-15 · Holder: Bvf Partners L P · Percent: 9.9% · SCHEDULE 13G/A
• Filed 2026-05-14 · Holder: Blue Owl Capital Holdings LP · Percent: 8.51% · SCHEDULE 13G/A
• Filed 2026-04-29 · Holder: Orbimed Advisors LLC · Percent: 13.1% · SCHEDULE 13D/A
• Filed 2026-04-21 · Holder: Omega Fund VI, L.P. · Percent: 8.4% · SCHEDULE 13D

ImageneBio, Inc. has 16 Schedule 13D or 13G filings on record since 2025-07-28. 6 holders' latest filing reports 5% or more of common stock, $0.001 par value. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind ImageneBio, Inc. and the warning signs.

See ImageneBio, Inc.'s free Snapshot Watch ImageneBio, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on ImageneBio, Inc. and the records around it.

The people at ImageneBio, Inc.

• Jean-Francois Formela is also named on 1 other Form D filing: Antares Therapeutics, Inc. (May 2025)

ImageneBio, Inc. elsewhere on the record

• Leadership changes Jul 2026
• Who owns it

Companies that share a holder

• Atlas Venture Fund X, L.P. also filed stake reports on 5 other companies: Kymera Therapeutics, Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026), Q32 Bio Inc. (May 2026)
• Blue Owl Capital Holdings LP also filed stake reports on 10 other companies: Context Therapeutics Inc. (Aug 2026), enGene Therapeutics Inc. (Aug 2026), Aktis Oncology, Inc. (May 2026)
• Funicular Funds, LP also filed stake reports on 10 other companies: AmpliTech Group, Inc. (Oct 2026), SYNLOGIC, INC. (Jul 2026), Rein Therapeutics, Inc. (May 2026)

Want the whole picture on ImageneBio, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on ImageneBio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on ImageneBio, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   19 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies ImageneBio, Inc. by CUSIP 45175G207 and gives its principal executive office as 12526 HIGH BLUFF DRIVE, SAN DIEGO, CA 92130 (SCHEDULE 13G/A, 2026-08-14).

What the percentages are based on

The following percentages are based upon a denominator that is the sum of: (i) 11,279,130 Shares outstanding as of June 30, 2026, as disclosed in the Issuer's Registration Statement on Form S-3 filed with the Securities and Exchange Commission on August 5, 2026 and (ii) 18,645 Shares issuable upon the exercise of certain Pre-Funded Warrants held by the Reporting Persons, as applicable.Bvf Partners L P, SCHEDULE 13G/A, 2026-08-14

Purpose of Transaction (Item 4)

BML Investment Partners, L.P.

All of the Common Stock of the Issuer reported on this Schedule 13D was acquired in the ordinary course of business by the reporting persons for investment purposes. The reporting persons have no present plans or proposals that relate to or would result in any of the actions described in Item 4(a) through (j) of Schedule 13D. The reporting persons may evaluate on a continuing basis the investment in the Issuer and may, from time to time, acquire or dispose of Common Stock of the Issuer. Any such acquisitions or dispositions will depend upon (i) the price and availability of the Issuer's securities; (ii) subsequent developments concerning the Issuer's business and prospects and the industry in which the Issuer operates; (iii) investment policies of the reporting persons; (iv) other investment opportunities available to the reporting persons; (v) general market and economic conditions; (vi) tax considerations; and (viii) such other factors as the reporting persons may deem relevant. Any such acquisitions or dispositions may be made, subject to applicable law, in open market transactions. On July 25th, the Issuer completed the transaction with Inmagene. The reporting person is no longer a 5% holder.Item 4 of the SCHEDULE 13D/A filed 2025-07-28

Atlas Venture Fund X, L.P.

Item 4 of the Statement is hereby amended and supplemented as follows: On December 23, 2024, Ikena, Insight Merger Sub I, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands and direct wholly owned subsidiary of Ikena ("Merger Sub I"), Insight Merger Sub II, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands and direct wholly owned subsidiary of Ikena ("Merger Sub II"), and Inmagene Biopharmaceuticals, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands (the "Inmagene"), entered into an Agreement and Plan of Merger (the "Merger Agreement"), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub I merged with and into Inmagene, pursuant to which Merger Sub I ceased to exist and was struck off the Register of Companies by the Registrar of Companies in the Cayman Islands (the "Registrar of Companies"), with Inmagene surviving (the "Surviving Entity") such merger as a direct, wholly owned subsidiary of Ikena (the "First Merger"), and immediately after the First Merger, the Surviving Entity merged with and into Merger Sub II, pursuant to which Inmagene ceased to exist and was struck off the Register of Companies by the Registrar of Companies, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Ikena …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-07-29; the filing has the rest

Orbimed Advisors LLC

The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-04-29; the filing has the rest

Omega Fund VI, L.P.

The Reporting Persons acquired their shares of Common Stock as an investment in the ordinary course of business. Stampacchia serves on the Issuer's board of directors. The Reporting Persons, either directly or indirectly through Stampacchia, may engage in discussions from time to time with the Issuer's board of directors, the Issuer's management or the Issuer's other stockholders. These discussions may be with respect to (i) acquiring or disposing of the shares or other securities of the Issuer; (ii) maintaining or changing the Issuer's business, operations, governance, management, strategy or capitalization; or (iii) implementing transactions that may relate to or may result in any matter set forth in paragraphs (a) through (j) of Item 4 of Schedule 13D. Additionally, the Reporting Persons may acquire additional securities through open market transactions, privately negotiated transactions or other methods. In connection with the foregoing, and as may be appropriate from time to time, each of the Reporting Persons may consider the feasibility and advisability of various alternative courses of action with respect to their investment in the Issuer, including, without limitation: (a) the acquisition or disposition by the Reporting Persons of the shares, including through derivative transactions which may include security-based swaps and short sales; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its …The first part of Item 4 of the SCHEDULE 13D filed 2026-04-21; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns ImageneBio, Inc.

Who owns ImageneBio, Inc.?

On this page, 6 holders' latest ownership filings report 5% or more of ImageneBio, Inc.: Orbimed Advisors LLC (13.1%, Schedule 13D/A, filed 2026-04-29), Bvf Partners L P (9.9%, Schedule 13G/A, filed 2026-08-14), Trails Edge Capital Partners, LP (9.9%, Schedule 13G, filed 2026-04-21), Blue Owl Capital Holdings LP (8.51%, Schedule 13G/A, filed 2026-05-14) and Omega Fund VI, L.P. (8.4%, Schedule 13D, filed 2026-04-21); 1 more is listed above.

Who are the largest shareholders of ImageneBio, Inc.?

By the share each holder's latest filing reports, the largest holders of ImageneBio, Inc. on this page are Orbimed Advisors LLC (13.1%), Bvf Partners L P (9.9%) and Trails Edge Capital Partners, LP (9.9%).

When did Orbimed Advisors LLC buy into ImageneBio, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Orbimed Advisors LLC on this page is the Schedule 13D/A, filed 2025-07-30, reporting 6.92%; its latest, Schedule 13D/A filed 2026-04-29, reports 13.1%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 16 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for ImageneBio, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for ImageneBio, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when ImageneBio, Inc. is mentioned again
• Find former ImageneBio, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes